Florida group opts for McKesson billing services

TriMed Staff | | Health Exec | Economics
Radiology Associates of South Florida has sourced its billing claims, support and reporting to McKesson’s Revenue Management Solutions, which will also offer financial analysis and performance assessment to the Miami-based radiology group.

McKesson’s Revenue Management Solutions department will provide the practice with financial analysis, updates on regulatory and compliance changes and web-based business intelligence and reporting tools, the company claimed.

McKesson provides health services and IT products and is based in San Francisco. Based in Gainesville, Radiology Associates of South Florida is a 66-physician group that performs diagnostic and interventional radiology procedures.

TriMed Staff

Related Content

Merck spends up to $2B to license new weight loss drug with potential heart benefits
Insulet wins $452M in lawsuit against rivals over medical device trade secrets
Medical device company cuts 70% of staff in push to meet Medtronic obligations
Cleerly’s momentum continues as AI specialists raise $106M
Operations manager, doctors charged in $70M imaging kickback scheme
Private-equity watchdog warns against nominating Marc Rowan as Treasury Secretary

Around the web

Cardiovascular Business
FDA says years-long tirzepatide shortage is resolved, will give limited leeway to compounders

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

AI in Healthcare
From Capitol Hill to a hospital near you? 5 federal recommendations for healthcare AI policy

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Cardiovascular Business
Merck spends up to $2B to license new weight loss drug with potential heart benefits

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.